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Two key routes of Francisella tularensis infection are through the skin and airway. We wished to understand
how the route of inoculation influenced the primary acute adaptive immune response. We show that an
intranasal inoculation of the F. tularensis live vaccine strain (LVS) with a 1,000-fold-smaller dose than an
intradermal dose results in similar growth kinetics and peak bacterial burdens. In spite of similar bacterial
burdens, we demonstrate a difference in the quality, magnitude, and kinetics of the primary acute T-cell
response depending on the route of inoculation. Further, we show that prostaglandin E2 secretion in the lung
is responsible for the difference in the gamma interferon (IFN-) response. Intradermal inoculation led to a
large number of IFN- T cells 7 days after infection in both the spleen and the lung. In contrast, intranasal
inoculation induced a lower number of IFN- T cells in the spleen and lung but an increased number of Th17
cells in the lung. Intranasal infection also led to a significant increase of prostaglandin E2 (PGE2) in the
bronchoalveolar lavage fluid. Inhibition of PGE2 production with indomethacin treatment resulted in in-
creased numbers of IFN- T cells and decreased bacteremia in the lungs of intranasally inoculated mice. This
research illuminates critical differences in acute adaptive immune responses between inhalational and dermal
infection with F. tularensis LVS mediated by the innate immune system and PGE2.
Francisella tularensis is a facultative intracellular bacterium
and the causative agent of tularemia. F. tularensis has a low
infective dose, high morbidity, and persistence in the environ-
ment (8). The two key routes of transmission are skin contact
and inhalation (6, 43, 44). There is a significant increase in
morbidity and mortality associated with inhalation infections
compared to skin contact infections in humans (43). The rea-
son for this difference is not clear. An F. tularensis live vaccine
strain (LVS) has been developed from an F. tularensis type B
strain as a vaccine and causes a less-severe disease in humans
(31), though infection in mice causes a fulminant disease that
is similar to human tularemia, which also varies in severity by
inoculation route (12). (All references to F. tularensis are to
LVS unless otherwise noted.) Genomic analysis demonstrates
that there is a high level of conservation on the genetic level
between F. tularensis LVS and both type A and type B strains,
though there are differences (34). Previous studies suggest a
difference in the innate immune response to F. tularensis be-
tween the intradermal and intranasal inoculation routes (2). A
careful characterization of acute adaptive immune responses,
comparing intradermal and intranasal infections with similar
tissue bacterial burdens, has not been performed.
T-cell-mediated responses are important in clearing primary
F. tularensis infection and conferring long-term immunity (4, 5,
10). Mice that lack an adaptive immune response are able to
partially control bacterial growth, but they fail to resolve in-
fection and eventually die (10). Secretion of gamma interferon
(IFN-) by T cells is important for clearance of F. tularensis
(11). Studies with IFN- receptor/ bone marrow macro-
phages suggest other cytokines are also able to aid in killing
intracellular F. tularensis. Interestingly, interleukin 12p35
knockout (IL-12p35/) mice are able to clear F. tularensis
with little to no IFN- response (9). IL-12p35/ mice still
generate Th17 T-cell responses following other bacterial infec-
tions (3, 20). Th17 T cells are a third effector CD4 T-cell
subset that is important in mucosal immunity and autoimmu-
nity (3, 20, 26, 35, 50). These T cells release IL-17, which
through action on epithelial cells recruits neutrophils to the
site of infection (24). These data suggest that IFN--mediated
responses are important in controlling F. tularensis infections,
although IL-17 and other T-cell-mediated responses may play
a part and become critical in the absence of IFN-.
We have demonstrated that F. tularensis infection of bone
marrow-derived macrophages leads to the production of pros-
taglandin E2 (PGE2) and alters subsequent T-cell activation in
vitro (49). A role for PGE2 during F. tularensis in vivo infection
has not yet been reported. In both humans and mice, PGE2 can
control dendritic-cell (DC) migration to the lymph node, block
IL-12 production, and promote IL-23 production (17, 18, 25,
28, 36–38, 51). Increased IL-23 would enhance the develop-
ment of Th17 cells (15). PGE2 also directly down modulates
human and mouse T-cell activity by decreasing calcium flux (an
early stage of T-cell activation) and blocking downstream pro-
duction of IL-2 and IFN- (1, 14, 22, 29, 42). Thus, bacterial
infections that induce PGE2 may alter T-cell function and gain
an advantage in vivo.
In this study, we compared acute primary T-cell-mediated
responses after intradermal and intranasal inoculations with F.
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tularensis. Intradermal inoculation led to an early and robust
IFN--mediated T-cell response, while intranasal inoculation
led to a mixed Th1/Th17- mediated cell response. PGE2 is at
least partially responsible for this difference, since inhibition of
PGE2 synthesis increased the IFN- response and decreased
the bacterial load in the lung. Studies reported in this article
highlight critical differences in the adaptive immune response
following different routes of inoculation with F. tularensis.
MATERIALS AND METHODS
Bacteria. The F. tularensis LVS (obtained as a vaccine preparation for the
Centers for Disease Control and Prevention) (4) was used in these studies.
Viable bacteria were quantified by serial dilution on chocolate agar.
Mice. C57BL/6J mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). All animals used in this study were maintained under specific-
pathogen-free conditions in the American Association of Laboratory Animal
Care-accredited University of North Carolina Department of Laboratory Animal
Medicine Facilities. Female mice between 6 and 8 weeks of age were used in all
studies.
Infection of mice. Mice were inoculated with F. tularensis LVS either intrana-
sally or intradermally. Intradermal inoculations were performed by injecting 105
CFU of F. tularensis LVS in 50 l of phosphate-buffered saline (PBS) at the base
of the tail. For intranasal inoculations, mice were anesthetized with an intraper-
itoneal injection of 0.4 ml of a 20-mg/ml tribromoethanol (Avertin) solution and
inoculated with 5  102 CFU of F. tularensis LVS in 50 l of PBS. Anesthetizing
mice with 0.4 ml of 20 mg/ml Avertin prior to intradermal inoculation had no
effect on the subsequent immune response (data not shown). These inoculation
doses were chosen because immunocompetent mice survived and resulted in
similar bacterial burdens in all tissues tested, allowing us to quantitatively com-
pare immune responses in the absence of an altered peak antigen load.
Collection of airway, lung, and spleen cells. Airway cells were collected by
bronchoalveolar lavage as previously described (48). Bronchoalveolar lavage
fluid (BALF) was collected and frozen at 80°C for later analysis. Cells were
placed in complete RPMI 1640 (RPMI 1640 supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 100 U/ml of penicillin, 100 g/ml streptomycin, and 50
M -mercaptoethanol). Mononuclear cells were isolated from the lung as
previously described (48). Mononuclear cells were purified from cell suspension
by density gradient centrifugation using Lympholyte M (Cedarlane Labs, On-
tario, Canada). Spleens were aseptically harvested from mice, and a single cell
suspension was generated. Red blood cells were removed by ammonium chlo-
ride-potassium carbonate lysis. Live cells from all tissues were determined using
trypan blue exclusion and counting on a hemacytometer. Greater than 90% cell
viability was noted in all samples.
Intracellular cytokine staining. For stimulator cells, naive C57BL/6J spleno-
cytes were plated in 24-well flat-bottom plates, 106 per ml, 2 ml per well, in
antibiotic-free medium and infected with F. tularensis LVS at an MOI of 200:1 or
mock infected. After 2 h, supernatants were removed and replaced with medium
containing 5 g/ml gentamicin to kill extracellular F. tularensis while leaving the
intracellular bacteria untouched. Splenocytes were then incubated at 37°C over-
night. The next day, adherent cells were extensively washed to remove T cells,
secreted cytokines, and PGE2. T cells from infected spleens were undetectable
after washes (data not shown). Tissue mononuclear cells from infected mice at
106 cells/ml were added to infected antigen-presenting cells (APCs) and cultured
for 24 h. Tissue APCs were added along with T cells to allow cross-presentation
of antigens in order to overcome any inhibitory effects on infected APCs. Strep-
tomycin was incubated at this step to kill all bacteria and ablate their inhibitory
effects. These parameters were chosen to maximize T-cell activation and mini-
mize the inhibitory effects of F. tularensis in in vitro assays, as demonstrated in
our lab (data not shown). For the last 4 h, cells were treated with 10 g/ml
brefeldin A. Cells were then stained for surface markers with fluorochrome-
conjugated antibodies. Cells were then fixed and stained for intracellular cyto-
kines, following the eBioscience protocol. Cells were analyzed on a CyAN ADP
flow cytometer (Dako, Fort Collins, CO). CyAN flow cytometry data were ana-
lyzed using the Summit software program, version 4.3 (Dako). All flow data
included appropriate 1 controls to allow correct compensation of multicolor
analysis.
Antibodies. The following directly conjugated antibodies were used in these
studies: fluorescein isothiocyanate-labeled anti-T-cell receptor beta (TCR)
clone H57 (eBioscience, San Diego, CA) used at 1.25 g/106 cells, phycoerythrin
(PE)-labeled anti-IFN- clone XMG1.2 (BD, Franklin Lakes, NJ) used at 1
g/106 cells, PE-Texas Red-labeled anti-CD11c clone N418 (Invitrogen, Carls-
bad, CA) used at 0.25 g/106 cells, peridinin chlorophyll protein-labeled anti-
CD8 clone Ly-2 (BD) used at 1 g/106 cells, peridinin chlorophyll protein-
labeled anti-GR-1 clone RB6-8C5 (BD) used at 0.33 g/106 cells, PE-Cy7-
labeled anti-CD19 clone 1D3 (BD) used at 0.2 g/106 cells, PacBlue-labeled
anti-NK1.1 clone PK136 (Biolegend, San Diego, CA) used at 1.25 g/106 cells,
PacOrange-labeled anti-CD4 clone RM4-5 (Invitrogen) used at 0.25 g/106 cells,
allophycocyanin-labeled anti-IL-17a clone TC11-18H10.1 (eBioscience) used at
2.5 g/106 cells, allophycocyanin-labeled anti-CD8 clone Ly-2 (BD) used at 0.5
g/106 cells, and APC-Alexa 750-labeled anti-CD11b clone M1/70 (eBioscience)
used at 0.5 g/106 cells. All antibodies were titrated and analyzed by multicolor
flow cytometry with a variety of cells before use.
T-cell analysis. After stimulation, cells were stained simultaneously with anti-
TCR, IFN-, CD11c, CD8, CD19, CD4, IL-17, and CD11b. A typical gating
scheme used for T-cell cytokine analysis is shown in Fig. 1A. Cells displayed in
Fig. 1A are from spleens harvested 7 days after intradermal inoculation. Cells
were selected by forward and side scatter; doublets were excluded by forward
linear scatter versus forward area scatter. Cells were then selected as CD11c,
CD11b, and CD19 negative, to exclude DCs, macrophages, and B cells.  T
cells were then identified by TCR expression, followed by CD4 or CD8 expres-
sion. These TCR, CD4 or CD8, CD11c, CD11b, and CD19 cells were
analyzed for IFN- and IL-17 expression. All gating is based on isotype controls.
Bronchoalveolar lavage flow analysis. Cells isolated from bronchoalveolar
lavage were stained with anti-TCR, -CD4, -CD8, -CD19, -CD11c, -CD11b,
-GR-1, and NK1.1. Cells were selected by forward and side scatter; doublets were
excluded by forward linear scatter versus forward area scatter. The bronchoal-
veolar lavage cell gating scheme is shown in Fig. 1B. T cells were defined as
TCR, CD4, or CD8 and negative for all other stains. B cells were defined
as CD19, NK cells as NK1.1, neutrophils as CD11bhi GR1hi, DCs as CD11c,
alveolar macrophages as CD11c CD11blow GR1mid, and macrophages as
CD11b CD11c. We are aware that this marker set fails to identify either B-cell
or DC subsets, but since neither of these populations contributes significantly to
either the IFN- or IL-17 responses, these markers are sufficient for our pur-
poses.
Enumeration of bacteria in organs. Lungs and spleens were collected and
homogenized in sterile PBS. Tenfold serial dilutions were plated on chocolate
agar and incubated at 37°C. Colonies were counted after 72 h.
Determination of secreted cytokines and prostaglandins. PGE2 in BALFs was
measured using a standard PGE2 enzyme immunoassay kit (Assay Design, Ann
Arbor, MI) with slight modifications to the standard protocol. BALF samples
were first treated with protein G-coupled Sepharose beads to remove murine
immunoglobulin G (IgG) in the samples. Capture plates were than pretreated
with PGE2 capture antibody for 15 min prior to addition of samples. Samples
were mixed with PGE2 conjugate and then placed on plates. The manufacturer’s
directions were then followed. Total IgG levels in BALF were also determined
at this time. There was no correlation between IgG levels and PGE2 levels (r2 
0.3232). IL-17 was measured using an enzyme-linked immunosorbent assay
(ELISA) kit (eBioscience) as per the manufacturer’s instructions. Analysis of
sample optical density was measured with a SpectraMax M2e microplate reader
(Molecular Devices, Sunnyvale, CA).
Statistical analysis. Data were analyzed using Student’s unpaired t test. The
GraphPad Prism 4.03 software program (Graphpad Software, San Diego, CA)
was used for analysis. Statistical significance was defined a P value of 0.05,
0.01, or 0.001. All data were pooled from a minimum of two experiments with
four mice per time point per group in each experiment.
RESULTS
Route of infection did not determine peak bacterial burden
in organs. We inoculated 6- to 8-week-old C57BL/6J female
mice either intradermally with 105 CFU or intranasally with 5 
102 CFU. Inoculation doses were confirmed by immediately
plating the inoculums on chocolate agar. At multiple times
after inoculation, the numbers of organisms in lung and spleen
tissue were determined. Early and late after inoculation, a
modestly increased bacterial burden was seen in the lung of
intranasally inoculated mice compared to results for intrader-
mally inoculated mice. At day 3 through day 7 postinoculation,
similar numbers of organisms were present in the lung regard-
less of the inoculation route (Fig. 2). Similar peak bacterial
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loads were seen in the lungs of intranasally and intradermally
inoculated mice. A delay in clearance was seen in the lungs of
intranasally inoculated mice. A trend in kinetics of accumula-
tion and clearance of bacteria similar to that in the lung was
seen in the spleen. The spleen was cleared of bacteria by day 14
postinoculation regardless of the route. The bacterial burden
was also similar in the liver between the two routes of inocu-
lation and was cleared in both groups by day 14 (data not
shown). These inoculation doses were used for further studies
since they resulted in similar bacterial burdens that were below
the lethal dose. This allowed to us to analyze differences in
acute primary adaptive immune responses. We have chosen to
focus on the mechanism of effective immune responses rather
than examining the failing immune response resulting in death.
Route of inoculation impacted composition of cells in lung
and spleen. Since the rate of clearance but not the peak bac-
terial burden varied with the route of inoculation, we hypoth-
esized that subsequent acute primary adaptive immune re-
sponses were different and were responsible for the difference
in clearance rates. Furthermore, in other bacterial infections,
the peak bacterial load, not the duration of infection, impacts
the magnitude of the acute primary adaptive immune response
(32, 46, 47). Initially we measured the total numbers of cells,
CD4 T cells, and CD8 T cells in the lungs and spleens after
both routes of infection. We intranasally or intradermally in-
oculated mice with F. tularensis. After inoculation, cells were
collected from the airways, lungs, and spleens. Cells were
counted and then stained for T-cell, B-cell, and APC markers.
B-cell and APC cell markers were used to excluded these cells
from T-cell analysis. Both routes of inoculation caused in-
creased cellularity in the lung and spleen, while only the intra-
nasal inoculation led to an increase in the number of cells in
the BALF (Fig. 3). As expected with a site of inflammation, a
variety of cell types increased in number. Both inoculation
routes led to an increased number of B cells (CD19), mac-
rophages (CD11b), DCs (CD11c), and NK cells (NK1.1
positive) in spleen and lung tissue (data not shown). Intrana-
sally inoculated mice showed significant cellular infiltration
into the bronchoalveolar space, including neutrophils, DCs,
and macrophages, with the largest percentage being neutro-
phils (Table 1). Both routes of inoculation led to increased
cellular inflammation in both the lung and spleen.
FIG. 1. Gating scheme for cell identification and intracellular cytokine staining. (A) Gating scheme used for identification of T cells and
characterization of intracellular cytokine expression. Staining of spleen cells from mice 7 days after intradermal inoculation is shown. (B) Cellular
characterization of neutrophils, alveolar macrophages, dendritic cells, and macrophages in the bronchoalveolar spaces. Staining of BAL cells from
mice 10 days post-intranasal inoculation is shown.
FIG. 2. Intranasal and intradermal infections have similar bacterial
burdens in tissue. C57BL/6J mice were inoculated with F. tularensis
LVS either intradermally (105 CFU) or intranasally (5  102 CFU).
Spleen and lungs from each mouse were assessed for bacterial loads at
indicated time points after infection. Asterisks denote statistical dif-
ference (*, P  0.05; **, P  0.01; ***, P  0.001). Error bars
represent standard errors of the means (n  8). All comparisons are
between routes of inoculation at each time point. Statistical analysis
was done using Student’s t test with log-transformed data. Data rep-
resented are a combination of two experiments with four mice per
group for a total of eight mice per group per time point.
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Intradermal inoculation led to an increase in the number of
CD4 T cells in the spleen at days 7 and 10 postinoculation
compared to results with intranasal inoculation, which led to
an increase in the number of CD4 T cells late in infection
(day 14) (Fig. 3). In the lung, intradermal inoculation led to a
significant increase in the numbers of both CD4 and CD8 T
cells at day 7 postinoculation, which returned to uninfected
levels by day 14. In contrast, the intranasally inoculated mice
had a delay in the increase of CD4 T cells (not increasing
until day 10), while there was no significant increase in the
number of CD8 T cells. Furthermore, only intranasal inocu-
lation led to an increase of T cells in the bronchoalveolar
space. Thus, the route of inoculation influenced the type, mag-
nitude, and kinetics of T-cell accumulation in the spleen and
lung.
Intradermal but not intranasal inoculation induced a ro-
bust IFN--mediated T-cell response. IFN--mediated adap-
tive T-cell responses are important for resolving F. tularensis
infection (4, 23, 41). The lung normally has an anti-inflamma-
tory environment characterized by high levels of PGE2 (45)
which could interfere with the generation of IFN--positive
(IFN-) T cells. We hypothesized that intranasal inoculation
fails to generate a robust IFN- T-cell immune response. At
various time points after inoculation, cells were collected from
lungs and spleens. Leukocytes from these samples were stim-
ulated with F. tularensis-infected splenocytes for 24 h. Cells
FIG. 3. Inoculation route influences T-cell numbers in tissue. C57BL/6J mice were inoculated with F. tularensis LVS either intradermally (105
CFU) (E) or intranasally (5  102 CFU) (F). Cells were isolated from the airway, lungs, and spleen of each mouse at indicated time points after
inoculation. Day zero represents mock-inoculated mice, used to determine basal numbers of cells in specific tissues. All comparisons are between
routes of inoculation at each time point. Asterisks denote statistical difference (*, P  0.05; **, P  0.01; ***, P * 0.001). Error bars represent
standard errors of the means (n  8). Data represented are a combined from two experiments with four mice per group for a total of eight mice
per group per time point.
TABLE 1. Cellular infiltration into the bronchoalveolar space after intradermal or intranasal inoculation
Daye Groupc
Cell countab
CD19 CD11c CD11c CD11blow GR1mid CD11b CD11bhi GR1hi NK1.1
0 Control 18 	 5 764 	 213 11,000 	 1,800 13 	 3 152 	 35 340 	 262
7 ID 7 	 7 875 	 55 13,000 	 2,300 19 	 7 111 	 26 1725 	 620d
IN 40 	 10 2,291 	 270d 7,600 	 1,200 1,083 	 147d 5,772 	 808d 698 	 69
10 ID 13 	 1 996 	 211 4,600 	 770 16 	 4 193 	 27 376 	 126
IN 316 	 107d 5,593 	 665d 7,300 	 130 1,870 	 361d 8,937 	 1375d 2,647 	 253d
14 ID 17 	 4 836 	 103 4,300 	 660 17 	 2 240 	 36 84 	 18
IN 9,644 	 4,677d 3,334 	 1,670 10,000 	 4,400 2,351 	 1,362d 3,452 	 1,362d 950 	 586
a Values are means 	 standard errors (eight samples per group).
b Cells were defined as B cells (CD19), DCs (CD11c), alveolar macrophages (CD11c CD11blow GR1mid), macrophages (CD11b CD11c), neutrophils
(CD11bhi GR1hi), or NK cells (NK1.1).
c ID, intradermally inoculated mice; IN, intranasally inoculated mice.
d Significant difference (P  0.05) between results for routes of inoculation at each time point as calculated by Student’s t test. Data represented are combined from
two experiments with four mice per group for a total of eight mice per group per time point.
e Day postinoculation. “0” indicates mock inoculation.
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were then stained for T-cell surface markers and intracellular
IFN-. Bronchoalveolar lavage cells were not collected and
stained for intracellular cytokines due to the low number of T
cells recovered. Preliminary studies also examined NK cells;
these cells did not contribute significantly to the IFN- re-
sponse (data not shown). In fact, at a day-7 postinoculation, T
cells made up more than 90% of the IFN- cells, and by days
10 and 14 postinoculation, more than 95% of the IFN- cells
were T cells. We chose to do intracellular cytokine staining,
versus accumulation of IFN-, since it allowed us to determine
the total number of responding T cells in a given tissue, not just
the general response. Figure 4A demonstrates representative
staining profiles of CD4 T cells in spleen tissue for day 7
postinoculation mice. Percentages shown are percentages of
CD4 T cells that were expressing either IFN- or IL-17.
Similar responses were seen by CD8 T cells in the spleen and
by CD4 and CD8 T cells in the lung. As can be seen with the
dot plots, intradermal inoculation led to a more-vigorous
IFN- T-cell response than intranasal inoculation. By day 7
post-intradermal inoculation, there was a significant increase
in the numbers of both CD4 and CD8 IFN- T cells in the
lung and spleen (Fig. 4B). In contrast, intranasal inoculation
produced only a modest number of IFN- T cells in either
organ. There was no significant increase in IFN- CD8 T
cells in the lungs of intranasally inoculated mice. Thus, intra-
dermal inoculation generated a robust IFN- T-cell-medi-
ated response not seen in intranasal inoculation, even in the
lungs.
Intranasal infection led to a Th17-cell response. Intranasally
inoculated mice still cleared a low dose of F. tularensis, even
without the generation of a robust IFN--mediated T-cell re-
sponse. Studies have demonstrated the importance of Th17-
cell-mediated responses in clearance of Klebsiella pneumoniae
and Mycobacterium tuberculosis from the lung (13, 19, 52). We
hypothesized that Th17 T cells were being generated after
intranasal but not intradermal inoculation with F. tularensis. At
various time points after inoculation, cells were collected from
lungs and spleens. BALF was collected at the same time. Leu-
kocytes from the spleen and lungs were stimulated with F.
tularensis-infected splenocytes for 24 h. Cells were then stained
for T-cell surface markers, intracellular IFN- and IL-17. The
concentration of IL-17 was determined in BALF by ELISA.
There was a significant CD4 IL-17 IFN- T-cell (Th17)
response in the lung after intranasal inoculation. By day 10,
there was a significant increase in the number of Th17 cells in
the lungs of intranasally inoculated mice (Fig. 5A) but not in
those of intradermally inoculated mice. At day 10, 50% of the
cytokine-positive CD4 T cells against F. tularensis were mak-
ing IL-17, and these were the only cells making IL-17. As
expected, these Th17 cells did not make IFN-, as seen in Fig.
5C. A small increase in Th17 cells was seen in spleen samples
from both intradermally and intranasally inoculated mice, but
there was no significant difference between intranasal and in-
tradermal inoculation, and it is only a minor component over-
all (6% of F. tularensis-specific CD4 T cells) (data not
shown). There was also a significant increase in the concentra-
tion of IL-17 within the BALF from intranasally inoculated
mice that was absent for intradermally inoculated mice (Fig.
5B). Thus, T-cell responses in the lung after intranasal inocu-
lation were a mix of both Th1- and Th17-mediated responses.
PGE2 release after intranasal inoculation affected genera-
tion of IFN- T-cell responses and clearance of F. tularensis.
We previously demonstrated that F. tularensis infection of mac-
rophages in vitro leads to the production of PGE2 and damp-
ens Th1-cell development (49). PGE2 can also block an IFN-
response and promote a Th17-cell response (14, 22, 39). We
hypothesized that PGE2 was affecting the acute adaptive im-
mune response generated after intranasal but not intradermal
inoculation. BALF collected at various time points after intra-
nasal and intradermal inoculation was tested for the accumu-
lation of PGE2. Both routes led to a significant increase in the
PGE2 concentration in the BALF on day 7 postinoculation
compared to results for mock-inoculated mice (day 0) (Fig.
6A). PGE2 levels in the BALF of intradermally inoculated
FIG. 4. Intradermal inoculation promotes an increased number of IFN- T cells. C57BL/6J mice were inoculated with F. tularensis LVS either
intradermally (105 CFU) (E) or intranasally (5  102 CFU) (F). Cells were isolated from the lungs and spleens of each mouse at indicated time
points after inoculation. (A) T cells were then analyzed for total numbers of CD4 IFN- or CD8 IFN- cells. Day zero represents
mock-inoculated mice, used to determine basal numbers of cells in specific tissues. All comparisons are between routes of inoculation at each time
point. Asterisks denote statistical difference (*, P  0.05; **, P * 0.01; ***, P * 0.001). Error bars represent standard errors of the means (n 
8). Data represented are combined from two experiments with four mice per group for a total of eight mice per group per time point.
(B) Representative dot plot histograms of CD4 T cells from the spleen on day 7 postinoculation.
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mice returned to control levels by day 10, while levels in the
BALF of intranasally inoculated mice continued to increase
from day 7 to day 14. Since we can detect PGE2 in the BALF
by day 7 postinoculation, it is likely that PGE2 is functioning
earlier and shaping the adaptive immune response in the lung.
Thus, intranasal inoculation led to a prolonged elevation of
PGE2 in the BALF.
We hypothesized that indomethacin treatment of intrana-
sally inoculated mice would lead to an increased IFN- T-cell
response and a decreased bacterial burden. Mice were either
intranasally or intradermally inoculated with F. tularensis and
then treated with indomethacin by intraperitoneal (i.p.) injec-
tion of 1 mg of indomethacin/kg of body weight in 1% di-
methylsulfoxide (DMSO) on days 5, 6, and 7 postinoculation.
Untreated mice were i.p. injected with 1% DMSO. To deter-
mine if indomethacin treatment was altering PGE2 levels,
BALF was collected at day 7. In preliminary studies, we dem-
onstrated no difference in PGE2 levels in the BALF of intra-
nasally inoculated mice treated with i.p. injections of PBS or
1% DMSO (data not shown). Treatment of mice with indo-
methacin led to a significant decrease in the amount of PGE2
in the BALF of intranasally inoculated mice (Fig. 6B). A sim-
ilar response was seen with intradermally inoculated mice
(data not shown).
Mice were intranasally or intradermally inoculated and
treated with indomethacin as described above. At days 7, 10,
and 14 postinoculation, leukocytes from spleen and lung tissue
were isolated and stimulated with F. tularensis-infected spleno-
cytes for 24 h, after which the numbers of IFN- cells, IL-17
cells, total cell populations, and bacteria were determined. The
treatment of mice with indomethacin changed the kinetics of
IFN- T-cell accumulation but not the peak level. Indometh-
acin treatment of mice did not affect the dynamics of the
responding cell populations, since there was no change in the
numbers of CD19, CD11c, CD11b, TCR CD4, or
CD8 cells in indomethacin-treated mice versus untreated
FIG. 5. Intranasally inoculated mice have increased number of
Th17 cells and increased IL-17 in lung tissue. C57BL/6J mice were
inoculated with F. tularensis LVS either intradermally (105 CFU) or
intranasally (5  102 CFU). BALF and cells were isolated from the
lungs of each mouse at indicated time points after inoculation. Day
zero represents mock inoculation mice, used to determine basal num-
bers of cells in lung tissue and the concentration of IL-17 in BLF. (A) T
cells were analyzed for total number of CD4 IL-17 cells. (B) BALF
was analyzed for IL-17 by ELISA. All comparisons are between routes
of inoculation at each time point. (C) Representative staining of CD4
T cells from the lungs of mice days 7 and 10 post-intranasal (IN) and
intradermal (ID) inoculation. Asterisks denote statistical difference
(**, P  0.01). Error bars represent standard errors of the means (n 
8). Error bars on some samples are smaller than the symbols. Data
represented are combined from two experiments with four mice per
group for a total of eight mice per group per time point.
FIG. 6. PGE2 delays the generation of IFN-
 T cells and inhibits
effective clearance of F. tularensis from the lung. C57BL/6J mice were
inoculated with F. tularensis LVS either intradermally (105 CFU) or
intranasally (5  102 CFU). (A) BALF was collected from all mice (n 
8) at indicated time points. BALF was analyzed for the concentration
of PGE2 using a standard ELISA. (B, C, D) C57BL/6J mice were
inoculated with F. tularensis LVS intranasally (5  102 CFU). At days
5, 6, and 7 postinoculation, mice were treated with 1 mg/kg indometh-
acin in intraperitoneal injections. Untreated mice were injected with
1% DMSO. (B) On day 7, BALF was isolated from all mice and
analyzed for the concentration of PGE2 using a commercial ELISA.
(C) On days 7, 10, and 14 postinoculation, cells were isolated from the
lungs of all mice. T cells were then analyzed for IL-17 and IFN-.
(D) On days 7, 10, and 14 postinoculation, the bacterial load was
determined in the lungs of all mice. Panel A comparisons are between
routes of inoculation at each given time point; panel B, C, and D
comparisons are between treated mice and untreated mice. Asterisks
denote statistical difference (*, P  0.05; **, P  0.01, ***, P  0.001).
Error bars represent standard errors of the means (n  8). Data
represented are combined from two experiments with four mice per
group for a total of eight mice per group per time point.
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mice (data not shown). Intranasally inoculated mice treated
with indomethacin showed a significant increase in the num-
bers of both CD4 and CD8 IFN--producing cells in the
lungs by day 10 postinoculation (Fig. 6C). Importantly, at this
time there was a 94% reduction in the absolute number of
bacteria within the lung tissue of treated mice (Fig. 6D). By day
14 postinoculation, the number of IFN- CD4 T cells for
the untreated mice was equivalent to that for the treated mice;
this also corresponds to increased clearance of organisms from
the lungs of the untreated mice. By day 7 postinoculation, 90%
of the IFN- cells in the lungs were also TCR, with the
other 10% not being any one dominant cell population, re-
gardless of treatment. At days 10 and 14 postinoculation, more
than 95% of the IFN- cells were also TCR (data not
shown). There was no change in the number of Th17 cells for
indomethacin-treated mice from that for untreated mice, sug-
gesting that Th17 and Th1 development are independent.
Treatment of intranasally inoculated mice with indomethacin
had no effect on the number of organisms in the spleen or the
number of IFN- T cells, nor did treatment of intradermally
inoculated mice with indomethacin have an effect on either the
organism burden or the T-cell response (data not shown).
Thus, intranasal infection of mice with F. tularensis led to a
prolonged elevation of PGE2 levels that altered the subsequent
immune response and organism clearance.
DISCUSSION
F. tularensis is able to infect through both the skin and lungs,
and the route has a dramatic impact on the disease course and
disease outcome. Here we demonstrate that acute primary
T-cell responses depend on the route of inoculation, since
regardless of the route, similar peak bacteria burdens are seen
in both the spleen and lung. Intradermal inoculation led to a
dominant IFN- T-cell response in both the lung and spleen.
Intranasal inoculation, however, produced a lower number
of IFN- T cells and a significant increase in the number of
Th17 cells. Interestingly, we see differences in the number of
responding T cells, even though the peak bacterial burden is
similar, which would suggest similar antigen loads for T-cell
stimulation. In fact, with delayed clearance of organisms from
the intranasally inoculated mice, we would expect increased
numbers of IFN- T cells. With other bacterial infection
models, it is the peak bacterial load that determines the mag-
nitude of the T-cell response (32, 46, 47), though this may
differ in F. tularensis infections. Since there are fewer IFN-
T cells in intranasally inoculated mice, we believe it is the
microenvironment of the initial T-cell activation that is shaping
the subsequent T-cell response, not the size of the bacterial
burden.
IFN--mediated T-cell responses are an important arm of
the immune response against F. tularensis (10, 11, 23). We
found that intradermal inoculation led to a significant increase
in the numbers of IFN- CD4 and CD8 T cells 7 days
postinoculation in both the lung and spleen. This response
rapidly returned to control levels by day 14 postinoculation,
and accordingly, bacteremia was resolved by day 14. In con-
trast, the accumulation of T cells in the spleen and lung after
intranasal inoculation was delayed. Even when there was an
increase in cell numbers, the numbers of IFN- T cells in the
lung after intranasal inoculation was significantly lower than
that after intradermal inoculation. Intranasally inoculated
mice fail to generate the same robust IFN- T-cell response
observed in intradermally inoculated mice.
Intranasally inoculated mice clear F. tularensis without a
robust IFN--mediated response. This is not surprising, since
IL-12p35/ mice clear F. tularensis and generate long-term
immunity, even in the presence of little to no IFN- (9). IL-
12p35/ mice still produce the IL-12p40 subunit, which com-
bines with the IL-23p19 subunit to make functional IL-23 (30),
an important mediator in stabilizing IL-17 expression in T cells
(16), consistent with the IL-17 responses we detected. This
would suggest that IL-17 can at least partially substitute for
IFN- in controlling F. tularensis. Th17 cells aid in the recruit-
ment of neutrophils by stimulating epithelial cells to secrete
granulocyte-macrophage colony-stimulating factor (21, 53).
Along with T-cell responses, we saw a significant neutrophil
infiltrate in the bronchoalveolar space of intranasally inocu-
lated mice. Interestingly, human neutrophils are unable to kill
F. tularensis (27). Other reports suggest that neutrophils are
important for intradermal infections (2, 40); however, these
studies are difficult to interpret, since they never determine
which cells are depleted by the RB6-8C5 antibody treatment.
This antibody, which depletes GR-1 cells, can deplete a variety
of cells, including DCs, macrophages, and lymphocytes (7).
Furthermore, a variety of macrophages express GR-1. In fact,
one study demonstrates that in the liver, the major cell group
infected with F. tularensis is GR-1 macrophages (33). Thus,
making unequivocal conclusions about neutrophils is impossi-
ble. Further studies need to be done to clarify the role of
neutrophils and IL-17 in tularemia. Since in humans neutro-
phils seem unlikely to kill F. tularensis, it would suggest that the
neutrophil response seen in intranasal infection, along with
IL-17, would be ill equipped to deal with a large dose of F.
tularensis.
Prostaglandins are known to be powerful mediators of im-
mune responses. The immunoregulatory properties of PGE2
are the best characterized of those of the known prostaglan-
dins. We have previously demonstrated the importance of
PGE2 in in vitro F. tularensis infection of macrophages (49).
We have also demonstrated in our laboratory that both Fran-
cisella novicida strain U112 and F. tularensis subsp. tularensis
strain Schu S4 induce PGE2 production from bone marrow-
derived macrophages (data not shown). It has also been clearly
defined that PGE2 is a major contributor to the microenviron-
ment of the lung (45). Intranasal inoculation led to a significant
increase in the amounts of PGE2 in the lung. Due to the
multiple receptors that PGE2 can bind, it has both inflamma-
tory and anti-inflammatory effects on immune cells (28). It is
well established that in both humans and mice, PGE2 leads to
increased cAMP levels within T cells, which blocks IFN- and
IL-2 production and subsequent T-cell proliferation and pro-
motes the production of the Th2 cytokine IL-5 (1, 14, 22). This
has also been documented in an in vivo setting (54). We dem-
onstrate that pharmacological inhibition of PGE2 production
led to increased IFN- T-cell numbers and a decreased bac-
terial burden in intranasally inoculated mice earlier than in
untreated mice. Indomethacin treatment had no effect on in-
tradermally inoculated mice (data not shown), suggesting that
PGE2 is more important in altering T-cell responses in the
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lung. We specifically waited until day 5 postinoculation to treat
mice with indomethacin to allow innate events to function
normally in the context of PGE2-mediated signaling but de-
crease during activation of adaptive T-cell responses. It is pos-
sible that the effect of decreased PGE2 is not directly affecting
the T-cell response but rather is affecting some unknown func-
tion. The simplest explanation, however, is that PGE2 is
directly blocking the generation of IFN- T cells and the
inhibition of PGE2 production alleviates this inhibition. Re-
gardless of the mechanism, inhibition of PGE2 production in
mice leads to both increased IFN- T cells and a decreased
bacterial burden, demonstrating that PGE2 is detrimental to
the host in clearance of F. tularensis. Further studies on the in
vivo role of PGE2 during F. tularensis infection are ongoing in
our laboratory.
ACKNOWLEDGMENTS
We thank Robert Maile and Benjamin G. Vincent for helpful con-
versations and critical comments on the manuscript.
This work was supported by the NIH/NIAID Southeast Regional Cen-
ter of Excellence for Emerging Infections and Biodefense (SERCEB)
(grant no. U54 AI 057157); M.D.W. was supported by a T32 training
grant (AI-007062) to the Division of Infectious Disease.
Author contributions are as follows: M.D.W., L.L.H., T.H.K., and
J.A.F. designed research; M.D.W. and L.L.H. performed research;
M.D.W., L.L.H., T.H.K., and J.A.F. analyzed data; and M.D.W. and
J.A.F. wrote the paper.
There is no conflicting financial interest among the authors.
REFERENCES
1. Betz, M., and B. S. Fox. 1991. Prostaglandin E2 inhibits production of Th1
lymphokines but not of Th2 lymphokines. J. Immunol. 146:108–113.
2. Conlan, J. W., R. KuoLee, H. Shen, and A. Webb. 2002. Different host
defences are required to protect mice from primary systemic vs pulmonary
infection with the facultative intracellular bacterial pathogen, Francisella
tularensis LVS. Microb. Pathog. 32:127–134.
3. Cooper, A. M., A. Kipnis, J. Turner, J. Magram, J. Ferrante, and I. M.
Orme. 2002. Mice lacking bioactive IL-12 can generate protective, antigen-
specific cellular responses to mycobacterial infection only if the IL-12 p40
subunit is present. J. Immunol. 168:1322–1327.
4. Cowley, S. C., and K. L. Elkins. 2003. Multiple T cell subsets control Fran-
cisella tularensis LVS intracellular growth without stimulation through mac-
rophage interferon gamma receptors. J. Exp. Med. 198:379–389.
5. Cowley, S. C., E. Hamilton, J. A. Frelinger, J. Su, J. Forman, and K. L.
Elkins. 2005. CD4-CD8- T cells control intracellular bacterial infections both
in vitro and in vivo. J. Exp. Med. 202:309–319.
6. Cronquist, S. D. 2004. Tularemia: the disease and the weapon. Dermatol.
Clin. 22:313–320, vi–vii.
7. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina.
2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in
mice. J. Leukoc. Biol. 83:64–70.
8. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher,
E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lil-
libridge, J. E. McDade, M. T. Osterholm, T. O’Toole, G. Parker, T. M. Perl,
P. K. Russell, and K. Tonat. 2001. Tularemia as a biological weapon: medical
and public health management. JAMA 285:2763–2773.
9. Elkins, K. L., A. Cooper, S. M. Colombini, S. C. Cowley, and T. L. Kieffer.
2002. In vivo clearance of an intracellular bacterium, Francisella tularensis
LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on
IL-12 p70. Infect. Immun. 70:1936–1948.
10. Elkins, K. L., T. R. Rhinehart-Jones, S. J. Culkin, D. Yee, and R. K. Win-
egar. 1996. Minimal requirements for murine resistance to infection with
Francisella tularensis LVS. Infect. Immun. 64:3288–3293.
11. Fortier, A. H., T. Polsinelli, S. J. Green, and C. A. Nacy. 1992. Activation of
macrophages for destruction of Francisella tularensis: identification of cyto-
kines, effector cells, and effector molecules. Infect. Immun. 60:817–825.
12. Fortier, A. H., M. V. Slayter, R. Ziemba, M. S. Meltzer, and C. A. Nacy. 1991.
Live vaccine strain of Francisella tularensis: infection and immunity in mice.
Infect. Immun. 59:2922–2928.
13. Happel, K. I., E. A. Lockhart, C. M. Mason, E. Porretta, E. Keoshkerian,
A. R. Odden, S. Nelson, and A. J. Ramsay. 2005. Pulmonary interleukin-23
gene delivery increases local T-cell immunity and controls growth of Myco-
bacterium tuberculosis in the lungs. Infect. Immun. 73:5782–5788.
14. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002.
Prostaglandins as modulators of immunity. Trends Immunol. 23:144–150.
15. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines
with divergent functions. Nat. Rev. Immunol. 5:521–531.
16. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J.
Lafaille, D. J. Cua, and D. R. Littman. 2006. The orphan nuclear receptor
RORt directs the differentiation program of proinflammatory IL-17 T
helper cells. Cell 126:1121–1133.
17. Kalinski, P., C. M. Hilkens, A. Snijders, F. G. Snijdewint, and M. L. Kapsen-
berg. 1997. Dendritic cells, obtained from peripheral blood precursors in the
presence of PGE2, promote Th2 responses. Adv. Exp. Med. Biol. 417:363–
367.
18. Kalinski, P., P. L. Vieira, J. H. Schuitemaker, E. C. de Jong, and M. L.
Kapsenberg. 2001. Prostaglandin E(2) is a selective inducer of interleukin-12
p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 het-
erodimer. Blood 97:3466–3469.
19. Khader, S. A., G. K. Bell, J. E. Pearl, J. J. Fountain, J. Rangel-Moreno, G. E.
Cilley, F. Shen, S. M. Eaton, S. L. Gaffen, S. L. Swain, R. M. Locksley, L.
Haynes, T. D. Randall, and A. M. Cooper. 2007. IL-23 and IL-17 in the
establishment of protective pulmonary CD4 T cell responses after vacci-
nation and during Mycobacterium tuberculosis challenge. Nat. Immunol.
8:369–377.
20. Khader, S. A., J. E. Pearl, K. Sakamoto, L. Gilmartin, G. K. Bell, D. M.
Jelley-Gibbs, N. Ghilardi, F. deSauvage, and A. M. Cooper. 2005. IL-23
compensates for the absence of IL-12p70 and is essential for the IL-17
response during tuberculosis but is dispensable for protection and antigen-
specific IFN-gamma responses if IL-12p70 is available. J. Immunol. 175:788–
795.
21. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and in-
flammation. Immunity 21:467–476.
22. Kvirkvelia, N., I. Vojnovic, T. D. Warner, V. Athie-Morales, P. Free, N.
Rayment, B. M. Chain, T. W. Rademacher, T. Lund, I. M. Roitt, and P. J.
Delves. 2002. Placentally derived prostaglandin E2 acts via the EP4 receptor
to inhibit IL-2-dependent proliferation of CTLL-2 T cells. Clin. Exp. Immu-
nol. 127:263–269.
23. Leiby, D. A., A. H. Fortier, R. M. Crawford, R. D. Schreiber, and C. A. Nacy.
1992. In vivo modulation of the murine immune response to Francisella
tularensis LVS by administration of anticytokine antibodies. Infect. Immun.
60:84–89.
24. Linden, A. 2001. Role of interleukin-17 and the neutrophil in asthma. Int.
Arch. Allergy Immunol. 126:179–184.
25. Luft, T., M. Jefford, P. Luetjens, T. Toy, H. Hochrein, K. A. Masterman, C.
Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky. 2002. Function-
ally distinct dendritic cell (DC) populations induced by physiologic stimuli:
prostaglandin E(2) regulates the migratory capacity of specific DC subsets.
Blood 100:1362–1372.
26. Matsuzaki, G., and M. Umemura. 2007. Interleukin-17 as an effector mol-
ecule of innate and acquired immunity against infections. Microbiol. Immu-
nol. 51:1139–1147.
27. McCaffrey, R. L., and L. A. Allen. 2006. Francisella tularensis LVS evades
killing by human neutrophils via inhibition of the respiratory burst and
phagosome escape. J. Leukoc. Biol. 80:1224–1230.
28. Nataraj, C., D. W. Thomas, S. L. Tilley, M. T. Nguyen, R. Mannon, B. H.
Koller, and T. M. Coffman. 2001. Receptors for prostaglandin E(2) that
regulate cellular immune responses in the mouse. J. Clin. Investig. 108:1229–
1235.
29. Okano, M., Y. Sugata, T. Fujiwara, R. Matsumoto, M. Nishibori, K.
Shimizu, M. Maeda, Y. Kimura, S. Kariya, H. Hattori, M. Yokoyama, K.
Kino, and K. Nishizaki. 2006. E prostanoid 2 (EP2)/EP4-mediated suppres-
sion of antigen-specific human T-cell responses by prostaglandin E2. Immu-
nology 118:343–352.
30. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N.
Yu, J. Wang, K. Singh, F. Zonin, E. Vaisberg, T. Churakova, M. Liu, D.
Gorman, J. Wagner, S. Zurawski, Y. Liu, J. S. Abrams, K. W. Moore, D.
Rennick, R. de Waal-Malefyt, C. Hannum, J. F. Bazan, and R. A. Kastelein.
2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with
biological activities similar as well as distinct from IL-12. Immunity 13:715–
725.
31. Pollitzer, R. 1967. History and incidence of tularemia in the Soviet Union; a
review, p. 1–103. Institute for Contemporary Russian Studies, Fordham
University, New York, NY.
32. Porter, B. B., and J. T. Harty. 2006. The onset of CD8-T-cell contraction is
influenced by the peak of Listeria monocytogenes infection and antigen dis-
play. Infect. Immun. 74:1528–1536.
33. Rasmussen, J. W., J. Cello, H. Gil, C. A. Forestal, M. B. Furie, D. G.
Thanassi, and J. L. Benach. 2006. Mac-1 cells are the predominant subset
in the early hepatic lesions of mice infected with Francisella tularensis. Infect.
Immun. 74:6590–6598.
34. Rohmer, L., M. Brittnacher, K. Svensson, D. Buckley, E. Haugen, Y. Zhou,
J. Chang, R. Levy, H. Hayden, M. Forsman, M. Olson, A. Johansson, R.
Kaul, and S. I. Miller. 2006. Potential source of Francisella tularensis live
2658 WOOLARD ET AL. INFECT. IMMUN.







vaccine strain attenuation determined by genome comparison. Infect. Im-
mun. 74:6895–6906.
35. Salvatore, C. M., M. Fonseca-Aten, K. Katz-Gaynor, A. M. Gomez, A. Me-
jias, C. Somers, S. Chavez-Bueno, G. H. McCracken, and R. D. Hardy. 2007.
Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12
knockout mice results in improved bacterial clearance and reduced pulmo-
nary inflammation. Infect. Immun. 75:236–242.
36. Scandella, E., Y. Men, S. Gillessen, R. Forster, and M. Groettrup. 2002.
Prostaglandin E2 is a key factor for CCR7 surface expression and migration
of monocyte-derived dendritic cells. Blood 100:1354–1361.
37. Schnurr, M., T. Toy, A. Shin, M. Wagner, J. Cebon, and E. Maraskovsky.
2005. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and
enhances IL-23 expression in human dendritic cells: a novel role for the
cAMP pathway. Blood 105:1582–1589.
38. Sheibanie, A. F., I. Tadmori, H. Jing, E. Vassiliou, and D. Ganea. 2004.
Prostaglandin E2 induces IL-23 production in bone marrow-derived den-
dritic cells. FASEB J. 18:1318–1320.
39. Sheibanie, A. F., J. H. Yen, T. Khayrullina, F. Emig, M. Zhang, R. Tuma,
and D. Ganea. 2007. The proinflammatory effect of prostaglandin E2 in
experimental inflammatory bowel disease is mediated through the IL-
233IL-17 axis. J. Immunol. 178:8138–8147.
40. Sjostedt, A., J. W. Conlan, and R. J. North. 1994. Neutrophils are critical for
host defense against primary infection with the facultative intracellular bac-
terium Francisella tularensis in mice and participate in defense against rein-
fection. Infect. Immun. 62:2779–2783.
41. Sjostedt, A., R. J. North, and J. W. Conlan. 1996. The requirement of tumour
necrosis factor-alpha and interferon-gamma for the expression of protective
immunity to secondary murine tularaemia depends on the size of the chal-
lenge inoculum. Microbiology 142:1369–1374.
42. Snijdewint, F. G., P. Kalinski, E. A. Wierenga, J. D. Bos, and M. L. Kapsen-
berg. 1993. Prostaglandin E2 differentially modulates cytokine secretion pro-
files of human T helper lymphocytes. J. Immunol. 150:5321–5329.
43. Tarnvik, A., and L. Berglund. 2003. Tularaemia. Eur. Respir. J. 21:361–373.
44. Titball, R. W., and P. C. Oyston. 2003. A vaccine for tularaemia. Expert
Opin. Biol. Ther. 3:645–653.
45. Vancheri, C., C. Mastruzzo, M. A. Sortino, and N. Crimi. 2004. The lung as
a privileged site for the beneficial actions of PGE2. Trends Immunol. 25:
40–46.
46. Williams, M. A., and M. J. Bevan. 2004. Shortening the infectious period
does not alter expansion of CD8 T cells but diminishes their capacity to
differentiate into memory cells. J. Immunol. 173:6694–6702.
47. Wong, P., and E. G. Pamer. 2001. Cutting edge: antigen-independent CD8 T
cell proliferation. J. Immunol. 166:5864–5868.
48. Woolard, M. D., L. M. Hodge, H. P. Jones, T. R. Schoeb, and J. W. Simecka.
2004. The upper and lower respiratory tracts differ in their requirement of
IFN-gamma and IL-4 in controlling respiratory mycoplasma infection and
disease. J. Immunol. 172:6875–6883.
49. Woolard, M. D., J. E. Wilson, L. L. Hensley, L. A. Jania, T. H. Kawula, J. R.
Drake, and J. A. Frelinger. 2007. Francisella tularensis-infected macrophages
release prostaglandin E2 that blocks T cell proliferation and promotes a
Th2-like response. J. Immunol. 178:2065–2074.
50. Wu, Q., R. J. Martin, J. G. Rino, R. Breed, R. M. Torres, and H. W. Chu.
2007. IL-23-dependent IL-17 production is essential in neutrophil recruit-
ment and activity in mouse lung defense against respiratory Mycoplasma
pneumoniae infection. Microbes Infect. 9:78–86.
51. Yang, L., N. Yamagata, R. Yadav, S. Brandon, R. L. Courtney, J. D. Morrow,
Y. Shyr, M. Boothby, S. Joyce, D. P. Carbone, and R. M. Breyer. 2003.
Cancer-associated immunodeficiency and dendritic cell abnormalities medi-
ated by the prostaglandin EP2 receptor. J. Clin. Investig. 111:727–735.
52. Ye, P., P. B. Garvey, P. Zhang, S. Nelson, G. Bagby, W. R. Summer, P.
Schwarzenberger, J. E. Shellito, and J. K. Kolls. 2001. Interleukin-17 and
lung host defense against Klebsiella pneumoniae infection. Am. J. Respir.
Cell Mol. Biol. 25:335–340.
53. Ye, P., F. H. Rodriguez, S. Kanaly, K. L. Stocking, J. Schurr, P. Schwarzen-
berger, P. Oliver, W. Huang, P. Zhang, J. Zhang, J. E. Shellito, G. J. Bagby,
S. Nelson, K. Charrier, J. J. Peschon, and J. K. Kolls. 2001. Requirement of
interleukin 17 receptor signaling for lung CXC chemokine and granulocyte
colony-stimulating factor expression, neutrophil recruitment, and host de-
fense. J. Exp. Med. 194:519–527.
54. Yin, H., L. Cheng, R. Langenbach, and C. Ju. 2007. Prostaglandin I(2) and
E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of
immune-mediated liver injury. Hepatology 45:159–169.
Editor: R. P. Morrison
VOL. 76, 2008 LUNG F. TULARENSIS INFECTION INDUCES Th17 AND PGE2 2659
 on July 16, 2020 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
